Treatment Strategies, Patterns of Drug Use and Treatment Discontinuation in Men with LUTS Suggestive of Benign Prostatic Hyperplasia: The Triumph Project

European Urology

Volumn 44, Issue 5, 2003, Pages 539-545

  Verhamme, K M C ^a   Dieleman, J P ^a   Bleumink, G S ^a   Bosch, J L H R ^a   Stricker, B H Ch ^a   Sturkenboom, M C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adherence; BPH; LUTS; Persistence; Treatment

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PRAZOSIN; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NETHERLANDS; PATIENT COMPLIANCE; PHYTOTHERAPY; POISSON DISTRIBUTION; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

EID: 0142197657     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00376-2     Document Type: Article

References (30)

1. Verhamme KMC, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MCJM. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-The Triumph Project. Eur Urol 2002;42:323-8.
2. Clifford GM, Logie J, Farmer RDT. How do symptoms indicative of BPH progress in real life practice? The UK experience. Eur Urol 2000;38(Suppl 1):48-53.
3. Workshop, treatment of benign prostatic hyperplasia. Medical Products Agency. 1997.
4. Therapeutics letter. Medical Management of Benign Prostatic Hyperplasia. 1997:19a-b.
5. Denis L, McConnell J, Yoshida O, Khoury S, Abrams P. Barry M, et al., the members of the Committees. Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy G, Yoshida O, editors. Proceedings of the 4th International Consultation on BPH. Plymouth: Plymbridge Distributors Ltd,; 1998. p. 669-84.
6. Klomp MLF, Germaca AJ, De Jonge-Wubben JGM, Mulders AHPW, Romeijnders ACM, Rosmalen CFH, et al. NHG standards, M42: difficult micturition in the elderly men. Huisarts en Wetenschap 1997;40:114-24.
7. Barry M, Roehrborn C, Webber R. Benign prostatic hyperplasia. Clin Evid 2002;8:849-63.
8. Farmacotherapeutisch kompas, 2000-2001. Uitgave van de Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen.
9. Chapple RC. Lower urinary tract symptoms suggestive of BPH-Triumph: design and implementation. Eur Urol 2001;39(Suppl 3):31-6.
10. Schrijvers AJP. Health and Health Care in The Netherlands. A critical self-assessment of Dutch experts in medical and health sciences. Utrecht: De Tijdstroom; 1997.
11. van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme WM, Boon WM, et al. The introduction of computer-based patient records in the Netherlands. Ann Int Med 1993;119(10):1036-41.
12. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. Family Pract 1992;9(3):330-9.
13. Anonymous, ATC and DDD values. Geneva: WHO; 1996.
14. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Method Inform Med 1999;38(4/5):339-44.
15. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neuro-urology and Urodynamics 2002;21:167-78.
16. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
17. Johnson RE, Hornbrook MC, Nichols GA. Replicating the chronic disease score (CDS) from automated pharmacy data. J Clin Epidemiol 1994;47:1191-9.
18. Michel MC, Goepel M. Lower urinary tract symptoms suggestive of benign prostatic obstruction-what's the long-term effectiveness of medical therapies. Eur Urol 2001;39(Suppl 3):20-5.
19. McNicholas TA. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the current practice patterns? Eur Urol 2001:39(Suppl 3):26-30.
20. Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how? Eur Urol 1999;36(Suppl 3):7-13.
21. Berges RR, Pientka L. Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 1999;36(Suppl 3):21-7.
22. Lukacs B. Management of symptomatic BPH in France: who is treated and how? Eur Urol 1999;36(Suppl 3):14-20.
23. Tubaro A, Montanari E. Management of symptomatic BPH in Italy: who is treated and how? Eur Urol 1999;36(Suppl 3):28-32.
24. McNicholas TA. Management of symptomatic BPH in the UK: who is treated and how? Eur Urol 1999;36(Suppl 3):33-9.
25. Lukacs B, Leplege A, Thibault P, Jardin A. Prospective study of men with clinical prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996;48:731-40.
26. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DF, et al. for the Hycat Investigator Group. The hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996;47:159-68.
27. Michel MC, Mehlburger L, Schumacher H, Bressel H, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163:1725-9.
28. Speakman M. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what is the available evidence for rational management. Eur Urol 2001;39(Suppl 3):6-12.
29. Speakman M. Initial choices and final outcomes in lower urinary tract symptoms. Eur Urol 2001;40(Suppl 4):21-30.
30. Speakman M. Who should be treated and how? Evidence-based medicine in symptomatic BPH. Eur Urol 1999;36(Suppl 3):40-51.